NCT05342493Recruiting
Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
AJOVY Subcutaneous Injection Long-term Specified Use-results Survey
Source: ClinicalTrials.gov · Last updated 22 Jun 2026
Brief summary (registry, in English)
To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 17 Apr 2022
- Start date
- 20 Apr 2022
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Diseases
- Migraine
- NCT number
- NCT05342493
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 20 Apr 2022 to the primary completion date, 30 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- patients with a known hypersensitivity to components of AJOVY
Who the study is looking for
- \-
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmacovigilance Department Coordinator of this site? Confirm its status | Osaka | Japan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.